TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

Mar 14, 2016, 08:58 ET from TapImmune Inc.

JACKSONVILLE, Florida, March 14, 2016 /PRNewswire/ --

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company's Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at 11.30 AM PT in Salon 5. The presentation will provide an update on clinical programs and pipeline development. TapImmune management will be available for one-on-one meetings at the conference.

The ROTH Conference will take place on March 13-16, 2016 at the Ritz-Carlton in Dana Point, California.

About TapImmune Inc. 

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov . The Company assumes no obligation to update the forward-looking statements.

CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-(866)-359-754

 

SOURCE TapImmune Inc.